Posted by ABMN Staff on May 7th, 2024
Moderna (NASDAQ:MRNA – Free Report) had its price target increased by Canaccord Genuity Group from $91.00 to $106.00 in a report published on Friday, Benzinga reports. Canaccord Genuity Group currently has a hold rating on the...
More of this article »